194 related articles for article (PubMed ID: 9158511)
1. Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumours: a prospective, randomized controlled study.
Ali-el-Dein B; Nabeeh A; el-Baz M; Shamaa S; Ashamallah A
Br J Urol; 1997 May; 79(5):731-5. PubMed ID: 9158511
[TBL] [Abstract][Full Text] [Related]
2. Early and large-dose intravesical instillation of epirubicin to prevent superficial bladder carcinoma recurrence after transurethral resection.
Mitsumori K; Tsuchiya N; Habuchi T; Li Z; Akao T; Ohyama C; Sato K; Kato T
BJU Int; 2004 Aug; 94(3):317-21. PubMed ID: 15291859
[TBL] [Abstract][Full Text] [Related]
3. Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study.
Ali-el-Dein B; el-Baz M; Aly AN; Shamaa S; Ashamallah A
J Urol; 1997 Jul; 158(1):68-73; discussion 73-4. PubMed ID: 9186325
[TBL] [Abstract][Full Text] [Related]
4. A randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder.
Koga H; Kuroiwa K; Yamaguchi A; Osada Y; Tsuneyoshi M; Naito S
J Urol; 2004 Jan; 171(1):153-7. PubMed ID: 14665865
[TBL] [Abstract][Full Text] [Related]
5. Intravesical 4'-epi-doxorubicin (epirubicin) versus bacillus Calmette-Guérin. A controlled prospective study on the prophylaxis of superficial bladder cancer.
Melekos MD; Chionis HS; Paranychianakis GS; Dauaher HH
Cancer; 1993 Sep; 72(5):1749-55. PubMed ID: 8348504
[TBL] [Abstract][Full Text] [Related]
6. A controlled study of intravesical epirubicin with or without alpha 2b-interferon as prophylaxis for recurrent superficial transitional cell carcinoma of the bladder. Finnish Multicentre Study Group.
Raitanen MP; Lukkarinen O
Br J Urol; 1995 Dec; 76(6):697-701. PubMed ID: 8535711
[TBL] [Abstract][Full Text] [Related]
7. Two instillations of epirubicin as prophylaxis for recurrence after transurethral resection of Ta and T1 transitional cell bladder cancer: a prospective, randomized controlled study.
Saika T; Tsushima T; Nasu Y; Miyaji Y; Saegusa M; Takeda K; Kumon H
World J Urol; 2010 Aug; 28(4):413-8. PubMed ID: 20054553
[TBL] [Abstract][Full Text] [Related]
8. Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional cell bladder tumours.
Rosen M
Br J Urol; 1997 Dec; 80(6):966. PubMed ID: 9439427
[No Abstract] [Full Text] [Related]
9. Intravesical instillation of epirubicin: effect on tumour recurrence in patients with dysplastic epithelium after transurethral resection of superficial bladder tumour.
Igawa M; Urakami S; Shirakawa H; Shiina H; Ishibe T; Kadena H; Usui T; Kawanishi M
Br J Urol; 1996 Mar; 77(3):358-62. PubMed ID: 8814838
[TBL] [Abstract][Full Text] [Related]
10. Transurethral resection with perioperative instilation on interferon-alpha or epirubicin for the prophylaxis of recurrent primary superficial bladder cancer: a prospective randomized multicenter study--Finnbladder III.
Rajala P; Liukkonen T; Raitanen M; Rintala E; Kaasinen E; Helle M; Lukkarinen O
J Urol; 1999 Apr; 161(4):1133-5; discussion 1135-6. PubMed ID: 10081854
[TBL] [Abstract][Full Text] [Related]
11. Intravesical instillations of 4-epi-doxorubicin (epirubicin) in the prophylactic treatment of superficial bladder cancer: results of a controlled prospective study.
Melekos MD; Dauaher H; Fokaefs E; Barbalias G
J Urol; 1992 Feb; 147(2):371-5. PubMed ID: 1732596
[TBL] [Abstract][Full Text] [Related]
12. [Intravesical instillation with epirubicin as a prophylactic treatment for superficial bladder cancer--using two different schedules].
Segawa N; Nishida T; Takahara K; Nomi H; Azuma H; Katsuoka Y
Hinyokika Kiyo; 2008 Nov; 54(11):711-6. PubMed ID: 19068724
[TBL] [Abstract][Full Text] [Related]
13. Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer.
Hendricksen K; Witjes WP; Idema JG; Kums JJ; van Vierssen Trip OB; de Bruin MJ; Vergunst H; Caris CT; Janzing-Pastors MH; Witjes JA
Eur Urol; 2008 May; 53(5):984-91. PubMed ID: 18248876
[TBL] [Abstract][Full Text] [Related]
14. The value of immediate postoperative intravesical epirubicin instillation as an adjunct to standard adjuvant treatment in intermediate and high-risk non-muscle-invasive bladder cancer: A preliminary results of randomized controlled trial.
Elsawy AA; El-Assmy AM; Bazeed MA; Ali-El-Dein B
Urol Oncol; 2019 Mar; 37(3):179.e9-179.e18. PubMed ID: 30448030
[TBL] [Abstract][Full Text] [Related]
15. [Intravesical instillation of epirubicin in the prophylactic treatment of recurrent superficial bladder cancer].
Kobayashi M; Sugaya Y; Yuzawa M; Morita T; Kobayashi Y; Tokue A
Hinyokika Kiyo; 1998 Dec; 44(12):861-4. PubMed ID: 10028430
[TBL] [Abstract][Full Text] [Related]
16. Intravesical epirubicin in the prophylaxis of superficial bladder cancer.
Sengör F; Beysel M; Erdoğan K; Erol A; Tuzluoğlu D
Int Urol Nephrol; 1996; 28(2):201-6. PubMed ID: 8836789
[TBL] [Abstract][Full Text] [Related]
17. Perioperative single dose instillation of epirubicin or interferon-alpha after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: a prospective randomized multicenter study--FinnBladder III long-term results.
Rajala P; Kaasinen E; Raitanen M; Liukkonen T; Rintala E;
J Urol; 2002 Sep; 168(3):981-5. PubMed ID: 12187204
[TBL] [Abstract][Full Text] [Related]
18. Comparing intra-arterial chemotherapy combined with intravesical chemotherapy versus intravesical chemotherapy alone: a randomised prospective pilot study for T1G3 bladder transitional cell carcinoma after bladder-preserving surgery.
Chen J; Yao Z; Qiu S; Chen L; Wang Y; Yang J; Li J
Cardiovasc Intervent Radiol; 2013 Dec; 36(6):1521-1526. PubMed ID: 23511989
[TBL] [Abstract][Full Text] [Related]
19. [Continuous intravesical instillation of epirubicin immediately after transurethral resection of superficial bladder cancer: a prospective controlled study].
Maekawa S; Suzuki H; Ohkubo K; Aoki Y; Okada T; Maeda H; Ogura K; Arai Y
Hinyokika Kiyo; 2000 May; 46(5):301-6. PubMed ID: 10876750
[TBL] [Abstract][Full Text] [Related]
20. The effects of intravesical chemoimmunotherapy with epirubicin and bacillus Calmette-Guérin for prophylaxis of recurrence of superficial bladder cancer: a preliminary report.
Uekado Y; Hirano A; Shinka T; Ohkawa T
Cancer Chemother Pharmacol; 1994; 35 Suppl():S65-8. PubMed ID: 7994790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
